YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Photo by BeInCrypto For the fourth year in a row, BeInCrypto is participating in Rio Innovation Week (RIW) with a stage dedicated to the future of finance, bringing together some of the key leaders in global financial market transformation…
Shares of Harmonic Inc(NASDAQ:HLIT) rose sharply in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Also, the company raised its FY26 EP…
* CEL-SCI (CVM) priced [https://seekingalpha.com/pr/20510195-cel-sci-corporation-announces-pricing-of-public-offering] a public offering of 6M shares of common stock at $1.20 per share, * Total gross proceeds from the offering, before dedu…
* Cel-Sci press release [https://seekingalpha.com/pr/20349741-cel-sci-reports-fiscal-2025-results] (CVM [https://seekingalpha.com/symbol/CVM]): FY research and development expenses were $15.9 million, which decreased by approximately $2.3…
(RTTNews) - Several small-cap names extended their momentum into after-hours trading on Thursday, posting sharp gains following active regular sessions. Recent strategic updates, leadership moves, and pipeline developments appear to be dri…
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TOP GAINERS TICKER CHANGE COMMENT OP…
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SOGP [https://www.chartmill.com/sto…
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down. [gap] GAP UP STOCKS TICKER CHANGE COMMENT SOGP [https://www.chartmill.com/stock/quote/SOGP/profi…
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT SPRC…
* CEL-SCI Corporation (NYSE:CVM [https://seekingalpha.com/symbol/CVM]) on Wednesday announced [https://seekingalpha.com/pr/20214061-cel-sci-announces-pricing-of-10-million-public-offering] the pricing of a public offering of 1,111,200 shar…
(RTTNews) - CEL-SCI Corp. (CVM), a clinical stage cancer immunotherapy company, announced the pricing of a public offering of about 1.11 million shares of its common stock at $9.00 per share. Total gross proceeds from the offering, before…
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. [topmovers] TOP GAINERS TICKER CHANGE COMMENT REPL [https://www.chartmill.com/stock/quote/REPL/profile] 95.47% REPLIMUNE GR…
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] GAINERS TICKER CHANGE COMMENT REPL [https://www.chartmill.com/stock…
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At CEL-SCI, a filing with the SEC revealed th…
* CEL-SCI (NYSE:CVM [https://seekingalpha.com/symbol/CVM]) announced on Friday the pricing of a best-efforts offering of 1,500,000 shares of its common stock. * Each share of common stock is being sold at an offering price of $3.82 per sha…
VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM), a clinical stage cancer immunotherapy company with a market capitalization of $26 million, announced Friday it has priced a best-efforts offering of 1.5 million shares of its common st…
Investing.com -- CEL-SCI Corporation (NYSE American:CVM) stock surged 25% after announcing a partnership with a leading Saudi pharmaceutical company for its cancer immunotherapy Multikine. The agreement covers regulatory and commercial act…
VIENNA - CEL-SCI Corporation (NYSE American:CVM) has reached an agreement with a leading Saudi Arabian pharmaceutical company to pursue regulatory approval and commercialization of its cancer immunotherapy Multikine in Saudi Arabia, accord…
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Fiscal Year 2023 Update CEL-SCI Corporation (NYSE:CVM) reported fiscal year 2023 on December 22nd after filing its Form 10-K with the SEC the previous day. 2023 has been…
VIENNA, Va., December 22, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments. Clinical and Corporate D…
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Multikine Selected as Potential New Standard of Care CEL-SCI Corporation (NYSE:CVM) provided a pleasant surprise earlier this week highlighting an announcement by the Bri…
VIENNA, Va., December 04, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine* (Leukocyte Interleukin, Injection)…
VIENNA, Va., November 20, 2023--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 2,49…
VIENNA, Va., November 16, 2023--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 2,490,000 shares of its common st…
In this article, we discuss the 12 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 5 Best Day Trading Stocks To Buy. Over the past few years, the rise of a new generation of stock trad…
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Multikine Clinical Data CEL-SCI Corporation (NYSE:CVM) has continued to generate data and analysis related to its IT-MATTERS trial - a Phase III study evaluating Multikin…
View the letter: https://cel-sci.com/wp-content/uploads/2023/10/CEL-SCI_shareholder_letter_from_CEO_Oct2023.pdf VIENNA, Va., October 30, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today released a letter to shareholder…
View the video: https://youtu.be/23WqSM9gI40 VIENNA, Va., October 24, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today released a video presentation in which the Company’s CEO, Geert Kersten, shares the most recent dat…
Target patient population for regulatory submissions finalized: Patients with low PD-L1, in contrast to current checkpoint inhibitors which work best with high PD-L1. Addressing unmet need in ~145,000 head and neck cancer patients per year…
Achieves significant milestones toward commissioning of manufacturing facility in preparation for Biologics License Application for regulatory approval submissions VIENNA, Va., October 19, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE A…
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Third Quarter Fiscal Year 2023 Update CEL-SCI Corporation (NYSE:CVM) reported third quarter fiscal year 2023 results in mid-August and filed its Form 10-Q with the SEC. S…
CEL-SCI will present the MHRA with new results that demonstrate pre-surgical response rates and overall survival advantagesthat are superior to those published by CEL-SCI previously, as a result of an improved selection algorithm that more…
Europe has 150,000 new head & neck cancer cases each year, more than twice the incidence in the U.S. VIENNA, Va., September 26, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported it has filed a request for Scien…
VIENNA, Va., August 11, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments. Clinical and Corporate Develo…
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) provided several updates in recent weeks. This includes details from its pre-submission meeting with the FDA, a poster presentation related…
VIENNA, Va., July 20, 2023--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 2,500,00…